FMR LLC reports 9.4% stake in Relay Therapeutics
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
FMR LLC reported beneficial ownership of 20,015,113.24 shares of Relay Therapeutics, Inc. common stock on a Schedule 13G, representing 9.4% of the class as of June 30, 2026. FMR has sole voting power over 19,967,458 shares and sole dispositive power over 20,015,113.24 shares, with no shared voting or dispositive power.
Abigail P. Johnson is listed as a reporting person with sole dispositive power over the same 20,015,113.24 shares and a 9.4% beneficial ownership of the class. One or more other persons have rights to receive dividends or sale proceeds from these securities, but no such person holds more than 5% of the outstanding common stock. FMR files as a parent holding company, with relevant subsidiaries identified in an attached Exhibit 99.
Key Figures
Key Terms
beneficially owned financial
Sole Voting Power financial
Sole Dispositive Power financial
Schedule 13G regulatory
parent holding company regulatory
power of attorney regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Relay Therapeutics (RLAY) does FMR LLC report owning?
What is Abigail P. Johnson’s reported ownership in Relay Therapeutics (RLAY)?
What type of security in Relay Therapeutics (RLAY) is reported by FMR LLC?
In what capacity is FMR LLC reporting its Relay Therapeutics (RLAY) stake?
AI-generated analysis. How Rhea-AI works. Not financial advice.